Per Rathenborg

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Maha Hussain, Karim Fizazi, Fred Saad et al. · New England Journal of Medicine · 2018 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

James L. Gulley, Michael Borre, Nicholas J. Vogelzang et al. · Journal of Clinical Oncology · 2019 · 278 citations · Full text

Medicine, Immunology, Oncology +17

Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study

Bertrand Tombal, Michael Borre, Per Rathenborg et al. · The Lancet Oncology · 2014 · 100 citations

Medicine, Pharmacology, Pharmacotherapy +12

Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate

Frederik Birkebæk Thomsen, Martin Andreas Røder, Per Rathenborg et al. · Scandinavian Journal of Urology · 2013 · 67 citations · Full text

Medicine, Oncology, Pharmacology +16

Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results

Bertrand Tombal, Michael Borre, Per Rathenborg et al. · European Urology · 2015 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17